CoChat

Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

With their resistance to genotoxic and anti-proliferative drugs and potential to grow tumors and metastases from very few cells, cancer stem or tumor-initiating cells (TICs) are a severe limitation for the treatment of cancer by conventional therapies. Here, we explored whether human T cells that are redirected via an EpCAM/CD3-bispecific antibody called MT110 can lyse colorectal TICs and prevent tumor growth from TICs. MT110 recognizes EpCAM, a cell adhesion molecule expressed on TICs from diverse human carcinoma, which was recently shown to promote tumor growth through engagement of elements of the wnt pathway. MT110 was highly potent in mediating complete redirected lysis of KRAS-, PI3 kinase- and BRAF-mutated colorectal TICs, as demonstrated in a soft agar assay. In immunodeficient mice, MT110 prevented growth of tumors from a 5,000-fold excess of a minimally tumorigenic TIC dose. T cells engaged by MT110 may provide a potent therapeutic means to eradicate TICs and bulk tumor cells derived thereof.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0013474

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Eradication of tumor-initiating CD44high/CD24high/EpCAMhigh HT-29 colorectal cells by MT110-engaged T cells. (A) Scheme of cytotoxicity assay with soft agar-based assay readout. (B) Photographs of soft agar plates with crystal violet-stained colonies growing from CD44high/CD24high/EpCAMhigh cells treated in the presence of T cells at the indicated concentrations of MT110, control BiTE antibodies at 100 ng/ml, or T cells alone. (C) Effect of MT110 on the number of CFUs per cm2. Bar graphs are mean values after 14 days from triplicate determinations +/− SD. Unstimulated PBMC were used as effector T cell source at an PBMC to HT-29 cell ratio of 10∶1.
Figure 1 Eradication of tumor-initiating CD44high/CD24high/EpCAMhigh HT-29 colorectal cells by MT110-engaged T cells. (A) Scheme of cytotoxicity assay with soft agar-based assay readout. (B) Photographs of soft agar plates with crystal violet-stained colonies growing from CD44high/CD24high/EpCAMhigh cells treated in the presence of T cells at the indicated concentrations of MT110, control BiTE antibodies at 100 ng/ml, or T cells alone. (C) Effect of MT110 on the number of CFUs per cm2. Bar graphs are mean values after 14 days from triplicate determinations +/− SD. Unstimulated PBMC were used as effector T cell source at an PBMC to HT-29 cell ratio of 10∶1.CC BY · PubMed Central
Figure 2 Eradication of primary colorectal tumor-initiating cells (TICs) by MT110-engaged T cells. (A) Photographs of crystal violet-stained colonies growing from TICs treated in the presence of T cells with the indicated concentrations of MT110, control BiTE antibodies at 200 ng/ml, or T cells alone. Unstimulated PBMCs were used as source of T cells at a PBMC to TIC ratio of 1∶1. (B) MT110 dose response of redirected lysis. Number of CFUs from TICs per cm2 are shown. Bar graphs are mean values of colony numbers from triplicate determination +/− SD observed after 11 days. Unstimulated PBMCs or CD8+ cells were used as effectors as indicated at an E:T ratio of 10∶1. (C) Effect of E:T ratio and T cell donor on redirected lysis. Number of CFUs per cm2 of TIC cells treated with 10 ng/ml MT110 or a CD3-monospecific BiTE control antibody at the indicated E:T ratios and incubation times are shown. Bar graphs are mean values of colony numbers from triplicate determination +/− SD as observed after 17 days. Unstimulated PBMCs from two healthy blood donors were used as effector cells. (D) Time dependence of redirected lysis. Number of CFUs per cm2 from TICs treated with 10 ng/ml MT110 or a CD3-monospecific BiTE control antibody at a PBMC to TIC ratio of 1∶1 are shown. Bar graphs are mean values from a triplicate determination +/− SD observed after 15 days.
Figure 2 Eradication of primary colorectal tumor-initiating cells (TICs) by MT110-engaged T cells. (A) Photographs of crystal violet-stained colonies growing from TICs treated in the presence of T cells with the indicated concentrations of MT110, control BiTE antibodies at 200 ng/ml, or T cells alone. Unstimulated PBMCs were used as source of T cells at a PBMC to TIC ratio of 1∶1. (B) MT110 dose response of redirected lysis. Number of CFUs from TICs per cm2 are shown. Bar graphs are mean values of colony numbers from triplicate determination +/− SD observed after 11 days. Unstimulated PBMCs or CD8+ cells were used as effectors as indicated at an E:T ratio of 10∶1. (C) Effect of E:T ratio and T cell donor on redirected lysis. Number of CFUs per cm2 of TIC cells treated with 10 ng/ml MT110 or a CD3-monospecific BiTE control antibody at the indicated E:T ratios and incubation times are shown. Bar graphs are mean values of colony numbers from triplicate determination +/− SD as observed after 17 days. Unstimulated PBMCs from two healthy blood donors were used as effector cells. (D) Time dependence of redirected lysis. Number of CFUs per cm2 from TICs treated with 10 ng/ml MT110 or a CD3-monospecific BiTE control antibody at a PBMC to TIC ratio of 1∶1 are shown. Bar graphs are mean values from a triplicate determination +/− SD observed after 15 days.CC BY · PubMed Central
Figure 3 Soft agar colonies from TICs implanted into NOD/SCID mice cause lymph node metastasis. (A) Representative photographs of lymph node metastases derived from s.c. implanted TIC-derived soft agar colonies. (B) Representative FACS analysis of cells derived from an s.c. tumor and a cervical lymph node of a NOD/SCID mouse s.c. implanted with a soft agar colony derived from TICs.
Figure 3 Soft agar colonies from TICs implanted into NOD/SCID mice cause lymph node metastasis. (A) Representative photographs of lymph node metastases derived from s.c. implanted TIC-derived soft agar colonies. (B) Representative FACS analysis of cells derived from an s.c. tumor and a cervical lymph node of a NOD/SCID mouse s.c. implanted with a soft agar colony derived from TICs.CC BY · PubMed Central
Figure 4 Cure of NOD/SCID mice receiving a 5,000-fold excess of a minimally tumor-initiating TIC-dose. (A) Mixtures of 5×105 TICs and 1×106 human PBMCs were inoculated into NOD/SCID mice (N = 3 for vehicle; N = 5 for vehicle + PBMCs; N = 4 for MT110 5 µg/kg; N = 3 for MT110 50 µg/kg and N = 3 for MT110 500 µg/kg group) and mice daily treated i.v. for 12 days with the indicated doses of MT110, or with vehicle controls in the absence and presence of PBMCs. The mean tumor volume is given. P-value was determined by Student's t-test. (B) Mixtures of 50,000 highly tumorigenic HT-29 xenograft-derived CD44high/CD24high/EpCAMhigh cells and 1×105 human PBMCs were inoculated into 5 NOD/SCID mice per group and mice daily treated i.v. for 12 days with the indicated doses of MT110, or with vehicle controls in the presence of PBMCs. The mean tumor volume is given. P-value was determined by Student's t-test. (C) Elimination of established tumors in NOD/SCID mice by treatment with MT110. Mixtures of 5×106 TICs and 1×107 human PBMCs were inoculated into 5 NOD/SCID mice per group to allow solid tumor formation. After tumor establishment at day 4 mice were treated i.v. for 14 days with 2.5 mg/kg of MT110, or with vehicle control in presence of PBMCs. The mean tumor volume is given. P-value was determined by Student's t-test.
Figure 4 Cure of NOD/SCID mice receiving a 5,000-fold excess of a minimally tumor-initiating TIC-dose. (A) Mixtures of 5×105 TICs and 1×106 human PBMCs were inoculated into NOD/SCID mice (N = 3 for vehicle; N = 5 for vehicle + PBMCs; N = 4 for MT110 5 µg/kg; N = 3 for MT110 50 µg/kg and N = 3 for MT110 500 µg/kg group) and mice daily treated i.v. for 12 days with the indicated doses of MT110, or with vehicle controls in the absence and presence of PBMCs. The mean tumor volume is given. P-value was determined by Student's t-test. (B) Mixtures of 50,000 highly tumorigenic HT-29 xenograft-derived CD44high/CD24high/EpCAMhigh cells and 1×105 human PBMCs were inoculated into 5 NOD/SCID mice per group and mice daily treated i.v. for 12 days with the indicated doses of MT110, or with vehicle controls in the presence of PBMCs. The mean tumor volume is given. P-value was determined by Student's t-test. (C) Elimination of established tumors in NOD/SCID mice by treatment with MT110. Mixtures of 5×106 TICs and 1×107 human PBMCs were inoculated into 5 NOD/SCID mice per group to allow solid tumor formation. After tumor establishment at day 4 mice were treated i.v. for 14 days with 2.5 mg/kg of MT110, or with vehicle control in presence of PBMCs. The mean tumor volume is given. P-value was determined by Student's t-test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. R Kischel, 2009, Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110., AACR 2009 poster presentation

Cited by

See all 85

Metadata

Authors
Herrmann, I., Baeuerle, P. A., Friedrich, M., Murr, A., Filusch, S., Rüttinger, D., Majdoub, M. W., Sharma, S., Kufer, P., Raum, T., & Münz, M.
Affiliations
University of California, Los Angeles (US)
Corresponding author
Baeuerle, Patrick A.
Venue
PLoS ONE
Published
2010-10-18
Volume
5
Issue
10
Pages
e13474
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2024837280
Cited by
85
References
50
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 9 · 2019: 7 · 2018: 3 · 2017: 7 · 2016: 2 · 2015: 7 · 2014: 8 · 2013: 10 · 2012: 13
FWCI
3.95
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
cancer stem cells, EpCAM, CD3, bispecific antibodies, T cell redirection, adoptive T cell therapy, tumor cell lysis, KRAS mutation, BRAF mutation, Wnt signaling
MeSH terms
Epithelial Cell Adhesion Molecule, Animals, Antigens, Neoplasm, Flow Cytometry, Humans, T-Lymphocytes, Colorectal Neoplasms, Cell Adhesion Molecules, Mice, SCID, Mice, Inbred NOD, CD3 Complex, Antibodies, Bispecific, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells. https://app.cochat.ai/papers/10.1371/journal.pone.0013474
The paper
Herrmann, I., Baeuerle, P. A., Friedrich, M., Murr, A., Filusch, S., Rüttinger, D., Majdoub, M. W., Sharma, S., Kufer, P., Raum, T., & Münz, M. (2010). Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells. PLoS ONE. https://doi.org/10.1371/journal.pone.0013474

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.